Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 2009

View Archived Issues

Ipilimumab shows antitumor activity in phase I trial in relapsed/refractory B-cell lymphoma

GSK and Valeant file NDA with FDA and MAA with EMEA for retigabine in epilepsy

Midodrine can reverse anejaculation

Long-lasting responses to VB4-845 seen in patients with bladder cancer

Vicor presents update on its activities during first nine months of 2009

Poly-ICLC combined with dendritic cell vaccine in phase I/II glioma trial

Bristol-Myers Squibb CB1 antagonists reduce weight in obesity models

New CB2 agonists active in chronic pain models reported by Neuroscienze PharmaNess

Chugai reports results from third quarter of 2009

Chugai's Avastin approved in Japan for additional indication in NSCLC

Johns Hopkins to host clinical study of Cel-Sci's LEAPS-H1N1 therapy

Data from 2 clinical trials support safety and efficacy of roflumilast in COPD therapy

Imatinib mesylate to be evaluated in phase III trial for PAH therapy

Histamine H4 receptor ligands for the treatment of pain in development at Abbott

Chiba University discovers novel oncolytic compounds

Takeda claims Smo receptor antagonists as oncolytics

Genervon identifies MNTF-derived peptides for neurodegenerative disorders

Xoma initiates phase II trial of XOMA-052 IL-1beta antibody in type 1 diabetes

FDA accepts and grants priority review to ChemGenex's NDA for Omapro in CML

Mologen seeks approval of phase I/II clinical trial of MGN-1601 in renal cancer

MorphoSys' phase Ib/IIa trial of MOR-103 in RA approved in Germany

FDA grants orphan drug status to Abraxane for pancreatic cancer and melanoma

AlphaVax progresses its prophylactic HSV vaccine

Biovitrum and Swedish Orphan merge to form Swedish Orphan Biovitrum

Astex signs CRADA with the NCI for anticancer HSP 90 inhibitor AT-13387

Spectrum and Nippon Kayaku enter collaboration for apaziquone in Asia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...